Cargando…

SO-1 The impact of COVID-19 on daily practice patterns in the third-line setting for patients with metastatic colorectal cancer: Results of a real-world survey

Detalles Bibliográficos
Autores principales:	Prager, G., Köhne, C., O’Connor, J., Rivera Herrero, F., Santini, D., Wasan, H., Phelip, J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Society for Medical Oncology. Published by Elsevier Ltd. 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8254384/ http://dx.doi.org/10.1016/j.annonc.2021.05.025

Ejemplares similares

The Screening and COnsensus Based on Practices and Evidence (SCOPE) Program–Results of a Survey on Daily Practice Patterns for Patients with mCRC
por: Prager, Gerald, et al.
Publicado: (2021)

Third-line treatment options in metastatic pancreatic cancer patients: a real-world study
por: Lu, Hong-Rui, et al.
Publicado: (2023)

Third-line treatment patterns and clinical outcomes for metastatic colorectal cancer: a retrospective real-world study
por: Deng, Ting, et al.
Publicado: (2023)

Real-world cost-effectiveness of cetuximab in the third-line treatment of metastatic colorectal cancer based on patient chart review in the Netherlands
por: Uyl-de Groot, Carin A., et al.
Publicado: (2018)

Treatment Settings and Outcomes with Regorafenib and Trifluridine/Tipiracil at Third-Line Treatment and beyond in Metastatic Colorectal Cancer: A Real-World Multicenter Retrospective Study
por: Signorelli, Carlo, et al.
Publicado: (2023)

A real-world study of anlotinib as third-line or above therapy in patients with her-2 negative metastatic breast cancer
por: Shao, Yingbo, et al.
Publicado: (2022)

Apatinib is effective as third-line and more treatment of advanced metastatic non-small-cell lung cancer: A retrospective analysis in a real-world setting
por: Leng, Jiao, et al.
Publicado: (2019)

Real-world data of fulvestrant as first-line treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer
por: Blancas, I., et al.
Publicado: (2021)

Different Toxicity Profiles Predict Third Line Treatment Efficacy in Metastatic Colorectal Cancer Patients
por: Unseld, Matthias, et al.
Publicado: (2020)

ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data
por: Moskovitz, Mor, et al.
Publicado: (2022)

A real-world analysis of nanoliposomal-irinotecan with 5-fluorouracil and folinic acid as third- or later-line therapy in patients with metastatic pancreatic adenocarcinoma
por: Chun, Jung Won, et al.
Publicado: (2022)

A real-world analysis of trametinib in combination with hydroxychloroquine or CDK4/6 inhibitor as third- or later-line therapy in metastatic pancreatic adenocarcinoma
por: Tang, Hui, et al.
Publicado: (2023)

The So-Called Third Heart-Sound
Publicado: (1908)

COVID-19 Fatigue: Not So Fast
por: O’Connor, Christopher M.
Publicado: (2020)

Real world evidence of Lenvatinib + anti PD-1 as an advanced line for metastatic melanoma
por: Stoff, Ronen, et al.
Publicado: (2023)

Real-world effectiveness of third- or later-line treatment in Japanese patients with HER2-positive, unresectable, recurrent or metastatic gastric cancer: a retrospective observational study
por: Sakai, Daisuke, et al.
Publicado: (2022)

Determinants of response to CDK4/6 inhibitors in the real-world setting
por: Witkiewicz, Agnieszka K., et al.
Publicado: (2023)

Cabozantinib real‐world effectiveness in the first‐through fourth‐line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
por: Gan, Chun Loo, et al.
Publicado: (2021)

Third-line docetaxel chemotherapy for recurrent and metastatic gastric cancer
por: Lee, Ji Hyun, et al.
Publicado: (2013)

Renal Denervation in Daily Practice: If So, How?
por: Millenaar, Dominic, et al.
Publicado: (2020)

Real-world effectiveness of third-line cabazitaxel in patients with metastatic castration-resistant prostate cancer: CARD-like analysis of data from a post-marketing surveillance in Japan
por: Matsuyama, Hideyasu, et al.
Publicado: (2023)

Oncologic Outcomes in Metastatic Colorectal Cancer with Regorafenib with FOLFIRI as a Third- or Fourth-Line Setting()()()
por: Ma, Cheng-Jen, et al.
Publicado: (2018)

Real‐world first‐line systemic therapy patterns in metastatic castration‐resistant prostate cancer
por: Anton, Angelyn, et al.
Publicado: (2021)

The Efficacy of Pyrotinib as a Third- or Higher-Line Treatment in HER2-Positive Metastatic Breast Cancer Patients Exposed to Lapatinib Compared to Lapatinib-Naive Patients: A Real-World Study
por: Ouyang, D. J, et al.
Publicado: (2021)

Real world outcomes with alpelisib in metastatic hormone receptor-positive breast cancer patients: A single institution experience
por: Alaklabi, Sabah, et al.
Publicado: (2022)

Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments
por: De Groot, S., et al.
Publicado: (2017)

Real-World Survival and Treatment Regimens Across First- to Third-Line Treatment for Advanced Triple-Negative Breast Cancer
por: Celik, Alan, et al.
Publicado: (2023)

A real-world analysis of second-line treatment options in pancreatic cancer: liposomal-irinotecan plus 5-fluorouracil and folinic acid
por: Kieler, Markus, et al.
Publicado: (2019)

Microsatellite stable metastatic colorectal cancer without liver metastasis may be preferred population for regorafenib or fruquintinib plus sintilimab as third-line or above therapy:A real-world study
por: Nie, Caiyun, et al.
Publicado: (2022)

Real-World Costs of Adverse Events in First-Line Treatment of Metastatic Non-Small Cell Lung Cancer
por: Engel-Nitz, Nicole M., et al.
Publicado: (2020)

Twice-daily versus once-daily lisinopril and losartan for hypertension: Real-world effectiveness and safety
por: Derington, Catherine G., et al.
Publicado: (2020)

Long-lasting response to third-line chemotherapy in metastatic pancreatic cancer
por: Tavares, Alda, et al.
Publicado: (2020)

Symptom study app provides real-world data on COVID-19 vaccines
por: Drury, Ruth E, et al.
Publicado: (2021)

Treatment Patterns in US Patients Receiving First-Line and Second-Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma in the Real World
por: King, Gentry, et al.
Publicado: (2022)

The real-world selection of first-line systemic therapy regimen for metastatic gastroenteropancreatic neuroendocrine neoplasm in Japan
por: Yamamoto, Shun, et al.
Publicado: (2022)

Real-World Experience with CDK4/6 Inhibitors for Metastatic HR+/HER2− Breast Cancer at a Single Cancer Center
por: Knudsen, Erik S, et al.
Publicado: (2022)

Real World Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Only Available Sunitinib and Pazopanib in First-Line Setting
por: Nikic, Predrag, et al.
Publicado: (2022)

P40 REAL-WORLD TREATMENT PATTERNS OF PATIENTS INITIATING THIRD-LINE THERAPY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA IN EUROPE
por: Lehne, M., et al.
Publicado: (2023)

The Microscope in Daily Practice, (Third Paper)
por: Danforth, I. N.
Publicado: (1875)

Efficacy of third-line therapy using bevacizumab in a patient with metastatic colorectal cancer
por: Gaulin, J., et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_1v25m5v5s4a6pa3f2nk5equ61b